ArticleClinical nuclear medicine2026
Prognostic Implications of Volume-based Quantitative 18F-FDG PET/CT Biomarkers in Pulmonary Sarcoidosis.
Article in Clinical nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnosis and treatment of sarcoidosis based on immunological etiology and mechanisms.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcoidosis is a multisystemic granulomatous disease with highly variable manifestations and outcomes, making clinical management challenging. This study evaluated the prognostic value of biomarkers derived from 18F-FDG PET/CT imaging. PATIENTS AND
methodsFrom an institutional registry, 75 sarcoidosis patients with a 18F-FDG PET/CT scan performed at the time of initial diagnosis were selected. A composite progression endpoint was defined, comprising either a decrease in FVC>5%, in DLCO>10%, a worsening of radiologic findings, increasing clinical symptoms, or death. Disease progression was assessed by onset at 1 year, 2 years, and overall. The MV of thoracic and extrathoracic lesions attributed to sarcoidosis was calculated, using a SUV threshold of 2.5. SUVmax was also determined for these regions.
resultsOf 75 patients, 45 patients met the progression criteria while 30 patients remained in remission. Baseline MVthoracic (P = 0.002) and MVwhole-body (P < 0.001) were higher in patients subsequently showing progression, while no significant differences were observed in whole-body or organ-specific SUVmax. The optimum threshold of MVthoracic for prognosis of overall disease progression was determined at 150 cm3, yielding an OR of 1.9 in the univariate analysis (MVthoracic >150 vs <150 cm3; 95% CI: 1.00-3.49; P = 0.049). For MVwhole-body, the optimal cutoff value was also determined at 150 cm3, with an OR of 2.06 (MVwhole body >150vs <150 cm3; 95% CI: 1.08-3.95; P = 0.029). Neither total nor organ-specific SUVmax had significant associations with progression outcomes.
conclusionsVolume-based biomarkers derived from 18F-FDG PET/CT were associated with disease progression in pulmonary sarcoidosis, whereas SUVmax showed no prognostic implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.